

Peter R Rossing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3128695/publications.pdf>

Version: 2024-02-01

607
papers

45,728
citations

2675

95
h-index

3034

188
g-index

633
all docs

633
docs citations

633
times ranked

31817
citing authors

#	ARTICLE	IF	CITATIONS
1	HbA1c and beyond. Nephrology Dialysis Transplantation, 2023, 38, 34-40.	0.7	1
2	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrology Dialysis Transplantation, 2023, 38, 372-383.	0.7	13
3	Design of the COmbinatiON effect of Flnerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrology Dialysis Transplantation, 2023, 38, 894-903.	0.7	48
4	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrology Dialysis Transplantation, 2022, 37, 1014-1023.	0.7	50
5	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <scp>GLPâ€RA</scp> treatment: A subgroup analysis from the <scp>FIDELIOâ€DKD</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 125-134.	4.4	41
6	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022, 101, 174-184.	5.2	53
7	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2022, 24, 281-288.	4.4	5
8	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports, 2022, 7, 36-45.	0.8	73
9	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal, 2022, 43, 474-484.	2.2	341
10	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. Journal of the American Society of Nephrology: JASN, 2022, 33, 225-237.	6.1	89
11	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology Dialysis Transplantation, 2022, 37, 1647-1656.	0.7	48
12	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, the, 2022, 10, 24-34.	11.4	40
13	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology Dialysis Transplantation, 2022, 37, 1261-1269.	0.7	32
14	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation, 2022, 145, 437-447.	1.6	86
15	QuÃ©telet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 827-837.	4.4	8
16	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 2022, 45, e888-e897.	8.6	20
17	Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology. Diabetes, Obesity and Metabolism, 2022, 24, 983-990.	4.4	5
18	The authors reply:. Kidney International, 2022, 101, 420-421.	5.2	1

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.8	6
20	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
21	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2022, 3, .	0.8	0
22	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.8	36
23	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	7.1	23
24	Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. <i>Kidney International Supplements</i> , 2022, 12, 27-35.	14.2	14
25	Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 1416-1427.	8.6	14
26	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	6.8	8
27	Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021. <i>American Journal of Medicine</i> , 2022, 135, 576-580.	1.5	5
28	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1638-1642.	4.4	1
29	Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism. <i>Frontiers in Endocrinology</i> , 2022, 13, 831793.	3.5	8
30	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	6.3	28
31	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. <i>Frontiers in Pharmacology</i> , 2022, 13, 799915.	3.5	3
32	FC083: Finerenone and Canagliflozin in the Treatment of Chronic Kidney Disease and Type 2 Diabetes: Matching-Adjusted Indirect Treatment Comparison of Fidelio-DKD and Credence. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	1
33	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
34	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
35	FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	3
36	Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes. <i>EBioMedicine</i> , 2022, 80, 104032.	6.1	7

#	ARTICLE	IF	CITATIONS
37	Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes. CKJ: Clinical Kidney Journal, 2022, 15, 2072-2080.	2.9	4
38	Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Kidney International, 2022, 102, 624-639.	5.2	18
39	Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Medicine, 2022, 11, 3573.	2.4	9
40	Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. Communications Biology, 2022, 5, .	4.4	17
41	Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes. Diabetes Research and Clinical Practice, 2022, 189, 109943.	2.8	2
42	Novel topical allogeneic bone-marrow-derived mesenchymal stem cell treatment of hard-to-heal diabetic foot ulcers: a proof of concept study. Stem Cell Research and Therapy, 2022, 13, .	5.5	5
43	Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal, 2022, 56, 256-263.	1.2	0
44	Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. Journal of Diabetes and Its Complications, 2022, 36, 108257.	2.3	5
45	Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	11
46	Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study. European Heart Journal Cardiovascular Imaging, 2021, 22, 1017-1025.	1.2	4
47	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 substudy. Diabetic Medicine, 2021, 38, e14405.	2.3	5
48	Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. Cardiovascular Research, 2021, 117, 600-612.	3.8	12
49	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. Journal of the American Society of Echocardiography, 2021, 34, 127-135.	2.8	10
50	A primer on metabolic memory: why existing diabetes treatments fail. CKJ: Clinical Kidney Journal, 2021, 14, 756-767.	2.9	2
51	Relationship between peripheral neuropathy, diastolic function and adverse cardiovascular outcome in individuals with type 1 diabetes mellitus without known cardiovascular disease: Results from the Thousand & 1 Study. Diabetes, Obesity and Metabolism, 2021, 23, 158-165.	4.4	4
52	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 2021, 143, 540-552.	1.6	171
53	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.	1.6	85
54	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	3.9	110

#	ARTICLE	IF	CITATIONS
55	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	1.9	88
56	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14459.	2.3	7
57	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	11.4	287
58	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 595-603.	8.6	5
59	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.6	53
60	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	5.2	42
61	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <i>Acta Diabetologica</i> , 2021, 58, 81-91.	2.5	24
62	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.7	15
63	Noninvasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. <i>Diabetic Medicine</i> , 2021, 38, e14517.	2.3	4
64	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. <i>Human Molecular Genetics</i> , 2021, 30, 393-409.	2.9	32
65	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021, 44, 1020-1026.	8.6	30
66	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <i>PLoS ONE</i> , 2021, 16, e0244402.	2.5	20
67	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	2.2	75
68	Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. <i>Journal of Diabetes</i> , 2021, 13, 754-763.	1.8	2
69	Metformin and carotid intima-media thickness in never-smokers with type 2 diabetes: The REMOVAL trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1371-1378.	4.4	11
70	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021, 9, 716-716.	1.7	5
71	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	2.7	47
72	A New Panel-Estimated GFR, Including β_2 -Microglobulin and β_2 -Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021, 77, 673-683.e1.	1.9	47

#	ARTICLE	IF	CITATIONS
73	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 10624.	3.3	8
74	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. <i>Kidney International</i> , 2021, 99, 1240-1241.	5.2	2
75	Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001944.	2.8	6
76	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	2
77	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> 2021;44:901â€“907. <i>Diabetes Care</i> , 2021, 44, e140-e141.	8.6	1
78	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	8.6	47
79	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021, 34, 1341-1359.	1.6	9
80	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. <i>Diabetologia</i> , 2021, 64, 1982-1989.	6.3	44
81	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021, 16, e0254859.	2.5	3
82	Successful glucose lowering therapy triumphs in heart failure. <i>EClinicalMedicine</i> , 2021, 37, 100996.	7.1	1
83	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	2.8	74
84	Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2098-2106.	8.6	22
85	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. <i>EClinicalMedicine</i> , 2021, 37, 100895.	7.1	45
86	Urinary peptidome and diabetic retinopathy in the DIRECTâ€Protect 1 and 2 trials. <i>Diabetic Medicine</i> , 2021, 38, e14634.	2.3	7
87	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012174.	2.6	18
88	The Low-Expression Variant of <i>FABP4</i> Is Associated With Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 2391-2401.	0.6	12
89	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2634-2651.	6.1	9
90	<sc>Sodiumâ€glucose</sc> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. <i>Nephrology</i> , 2021, 26, 1007-1017.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy. <i>Scientific Reports</i> , 2021, 11, 15208.	3.3	8
92	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021, 100, 215-224.	5.2	182
93	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	6.1	88
94	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. <i>Diagnostics</i> , 2021, 11, 1431.	2.6	5
95	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	1.7	10
96	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	27.0	599
97	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. <i>Diabetes</i> , 2021, 70, 2683-2693.	0.6	26
98	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	3.7	12
99	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2651-2659.	4.4	7
100	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	4.1	49
101	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002395.	2.8	14
102	New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. <i>New England Journal of Medicine</i> , 2021, 385, 1737-1749.	27.0	1,236
103	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911.	6.1	9
104	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18522.	3.3	21
105	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 901-907.	8.6	16
106	Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2263-2273.	0.7	12
107	Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021, 70, 39-50.	0.6	12
108	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	1.5	6

#	ARTICLE	IF	CITATIONS
109	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002289.	2.8	7
110	Making Use of Comparable Health Data to Improve Quality of Care and Outcomes in Diabetes: The EUBIROD Review of Diabetes Registries and Data Sources in Europe. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2021, 2, .	0.8	3
111	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	11.4	87
112	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	11.4	86
113	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. <i>Frontiers in Endocrinology</i> , 2021, 12, 790405.	3.5	16
114	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 290-297.	1.4	1
115	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. <i>Frontiers in Endocrinology</i> , 2021, 12, 780679.	3.5	4
116	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
117	Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease – Longitudinal observations of the PRIORITY study. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107467.	2.3	4
118	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 221-228.	6.3	368
119	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	8.6	846
120	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 145-151.	2.0	19
121	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	5.2	692
122	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 180.	6.8	7
123	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	27.0	2,523
124	Metformin and cardiorenal outcomes in diabetes: A reappraisal. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 904-915.	4.4	36
125	Association between severe diabetic retinopathy and lectin pathway proteins – an 18-year follow-up study with newly diagnosed type 1 diabetes patients. <i>Immunobiology</i> , 2020, 225, 151939.	1.9	3
126	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 11561.	3.3	8

#	ARTICLE	IF	CITATIONS
127	Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1696-1698.	4.5	0
128	Carotidâ€Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e017165.	3.7	22
129	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, 2217-2226.	0.6	40
130	TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4958-e4960.	3.6	1
131	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107707.	2.3	22
132	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. <i>American Journal of Nephrology</i> , 2020, 51, 839-848.	3.1	10
133	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	27.0	1,148
134	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.7	107
135	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. <i>Diabetologia</i> , 2020, 63, 2713-2724.	6.3	27
136	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1â€7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 880-893.	11.4	86
137	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pumpâ€Treated Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2882-2885.	8.6	49
138	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. <i>European Journal of Epidemiology</i> , 2020, 35, 685-697.	5.7	9
139	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020, 33, 931-948.	2.0	13
140	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	27.0	228
141	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882092882.	3.2	38
142	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020, 98, 839-848.	5.2	193
143	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <sc>LEADER</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	4.4	10
144	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 274-282.	0.7	168

#	ARTICLE	IF	CITATIONS
145	Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1289-1291.	5.3	7
146	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	11.4	166
147	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 16.	6.8	16
148	Describing the fecal metabolome in cryogenically collected samples from healthy participants. <i>Scientific Reports</i> , 2020, 10, 885.	3.3	10
149	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107590.	2.3	24
150	Hyperoxia improves autonomic function in individuals with long duration type 1 diabetes and macroalbuminuria. <i>Diabetic Medicine</i> , 2020, 37, 1561-1568.	2.3	9
151	Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107593.	2.3	4
152	Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2275-2287.	3.6	24
153	Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. <i>Clinical Biochemistry</i> , 2020, 83, 49-56.	1.9	23
154	Performance of Indexed and Nonindexed Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2020, 76, 446-449.	1.9	19
155	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020, 15, e0243737.	2.5	13
156	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. <i>European Journal of Endocrinology</i> , 2020, 182, 481-488.	3.7	10
157	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. <i>Methods in Molecular Biology</i> , 2020, 2067, 287-306.	0.9	3
158	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. <i>Diabetes</i> , 2020, 69, .	0.6	0
159	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.6	1
160	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. <i>Diabetes</i> , 2020, 69, 1532-P.	0.6	0
161	1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.6	1
162	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.7	5

#	ARTICLE	IF	CITATIONS
163	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. European Heart Journal Supplements, 2020, 22, O78-O86.	0.1	15
164	The History of Prevention and Treatment of Diabetic Nephropathy. Frontiers in Diabetes, 2020, , 242-256.	0.4	2
165	Prognostic utility of early systolic lengthening by speckle tracking echocardiography in patients with type 2 diabetes. European Heart Journal, 2020, 41, .	2.2	0
166	Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes. Circulation, 2020, 142, .	1.6	0
167	Cardiac time intervals predict major adverse cardiovascular events in individuals with type 1 diabetes without known heart disease. European Heart Journal, 2020, 41, .	2.2	0
168	Title is missing!. , 2020, 15, e0243737.		0
169	Title is missing!. , 2020, 15, e0243737.		0
170	Title is missing!. , 2020, 15, e0243737.		0
171	Title is missing!. , 2020, 15, e0243737.		0
172	Title is missing!. , 2020, 15, e0243737.		0
173	Title is missing!. , 2020, 15, e0243737.		0
174	Title is missing!. , 2020, 15, e0243737.		0
175	Title is missing!. , 2020, 15, e0243737.		0
176	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES â€” A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	4
177	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) â€” A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	4
178	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1760-1768.	8.6	30
179	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Functionâ€”Even Without Albuminuria. Diabetes Care, 2019, 42, 1886-1894.	8.6	99
180	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	6.1	135

#	ARTICLE	IF	CITATIONS
181	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2019, 62, 2354-2364.	6.3	23
182	Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. <i>Scientific Reports</i> , 2019, 9, 16398.	3.3	62
183	Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2019, 18, 114.	6.8	57
184	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits. <i>JAMA Network Open</i> , 2019, 2, e1910915.	5.9	41
185	Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1362-1365.	0.8	5
186	Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients. <i>Metabolites</i> , 2019, 9, 184.	2.9	22
187	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. <i>American Journal of Hypertension</i> , 2019, 32, 1146-1153.	2.0	17
188	Editorial: Novel Biomarkers for Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 649.	3.5	22
189	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1261-1265.	4.4	9
190	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1512-1520.	8.6	77
191	Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011779.	3.7	12
192	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 515-527.	11.4	180
193	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	21.4	549
194	Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. <i>Diabetologia</i> , 2019, 62, 1575-1580.	6.3	19
195	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019, 8, 779.	2.4	61
196	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
197	Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2006-2011.	4.4	44
198	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	5.2	26

#	ARTICLE	IF	CITATIONS
199	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 119-124.	1.7	3
200	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 429-441.	11.4	137
201	Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1171-1178.	1.2	15
202	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1112-1119.	8.6	38
203	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1088-1094.	8.6	61
204	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. <i>Kidney International</i> , 2019, 95, 1287-1288.	5.2	2
205	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. <i>Acta Diabetologica</i> , 2019, 56, 711-712.	2.5	12
206	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1277-1286.	0.6	13
207	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , 2019, 393, 1937-1947.	13.7	408
208	Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 289-296.	2.0	5
209	3080 Postsystolic shortening yields novel and independent prognostic information on cardiovascular events and mortality in patients with type 2 diabetes. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
210	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> 2019;42:1088-1094. <i>Diabetes Care</i> , 2019, 42, e188-e188.	8.6	2
211	OBESITY REMAINS A MAJOR RISK FACTOR ASSOCIATED WITH VASCULAR STIFFENING IN TYPE 2 DIABETES. <i>Journal of Hypertension</i> , 2019, 37, e65.	0.5	0
212	Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 818.	3.5	40
213	A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria. <i>Diabetologia</i> , 2019, 62, 292-305.	6.3	29
214	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 720-725.	4.4	15
215	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 736-740.	4.4	16
216	Clinical Features and Natural Course of Diabetic Nephropathy. , 2019, , 21-32.		5

#	ARTICLE	IF	CITATIONS
217	Predictive value of echocardiography in Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 687-693.	1.2	25
218	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. <i>Diabetes Care</i> , 2019, 42, 93-101.	8.6	37
219	Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder. <i>American Journal of Kidney Diseases</i> , 2019, 73, 293-296.	1.9	3
220	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800176.	1.6	16
221	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 796-803.	1.2	13
222	Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 98-102.	2.0	13
223	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 47-56.	2.0	17
224	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 659-666.	0.7	17
225	Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 171-177.	2.3	3
226	Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. <i>ELife</i> , 2019, 8, .	6.0	12
227	237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Stroke—The Steno-2 Study. <i>Diabetes</i> , 2019, 68, 237-OR.	0.6	0
228	456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 456-P.	0.6	0
229	526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy. <i>Diabetes</i> , 2019, 68, 526-P.	0.6	0
230	40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetes—An 18-Year Follow-Up Study. <i>Diabetes</i> , 2019, 68, 40-LB.	0.6	1
231	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	1.9	3
232	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	1.9	5
233	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw406.	0.7	29
234	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) — Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 181-190.	2.0	27

#	ARTICLE	IF	CITATIONS
235	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 470-473.	2.3	9
236	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2018, 41, 1493-1500.	8.6	51
237	Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 325-329.	2.3	12
238	Diagnosis of diabetic kidney disease: state of the art and future perspective. <i>Kidney International Supplements</i> , 2018, 8, 2-7.	14.2	202
239	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018, 35, 392-393.	2.3	6
240	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2018, 17, 50.	6.8	36
241	Subclassification of diabetes based on quantitative traits. <i>Nature Reviews Nephrology</i> , 2018, 14, 355-356.	9.6	2
242	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.6	136
243	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018, 14, S31-S37.	0.5	35
244	Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients—the Thousand & 1 Study. <i>Acta Diabetologica</i> , 2018, 55, 21-29.	2.5	6
245	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1034-1041.	1.2	23
246	Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20-year life-course study in an inception cohort. <i>Diabetologia</i> , 2018, 61, 231-241.	6.3	20
247	SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i488-i488.	0.7	0
248	SP420ALTERED LEVELS OF PLASMA LIPIDS ARE ASSOCIATED WITH DIABETIC KIDNEY DISEASE: A CROSS-SECTIONAL STUDY OF PLASMA LIPIDOMICS IN TYPE 1 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i489-i489.	0.7	0
249	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. <i>Journal of Hypertension</i> , 2018, 36, e147.	0.5	0
250	SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPATHY. <i>Journal of Hypertension</i> , 2018, 36, e240.	0.5	0
251	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 925-933.	11.4	30
252	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018, 61, 2461-2498.	6.3	1,002

#	ARTICLE	IF	CITATIONS
253	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2018, 41, 2669-2701.	8.6	2,190
254	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1133-1140.	2.3	9
255	Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018, 7, e008856.	3.7	16
256	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	2.3	14
257	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 870-878.	11.4	95
258	Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a case-control study. <i>Diabetic Medicine</i> , 2018, 35, 1337-1344.	2.3	10
259	Characteristics of high- and low-risk individuals in the <sc>PRIORITY</sc> study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.	2.3	24
260	Stratification of type 2 diabetes based on routine clinical markers. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 275-283.	2.8	41
261	Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study. <i>Journal of Electrocardiology</i> , 2018, 51, S72-S77.	0.9	6
262	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. <i>PLoS ONE</i> , 2018, 13, e0196634.	2.5	29
263	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1596-1604.	2.3	16
264	Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 61.	6.8	29
265	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018, 55, 1143-1150.	2.5	23
266	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21Åyears of follow-up in the randomised Steno-2 study. <i>Diabetologia</i> , 2018, 61, 1724-1733.	6.3	66
267	Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria – A Path for Improved Renoprotection?. <i>American Journal of the Medical Sciences</i> , 2018, 355, 407-408.	1.1	0
268	How Does Risk Screening for Kidney Disease Influence Diabetes Distress?. <i>Diabetes</i> , 2018, 67, .	0.6	0
269	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.7	73
270	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw292.	0.7	66

#	ARTICLE	IF	CITATIONS
271	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	62
272	Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot – does quantitative data improve diagnostic value?. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 30-36.	1.2	8
273	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, e32-e33.	8.6	4
274	Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 391-397.	8.6	40
275	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	4.4	39
276	Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans. <i>EBioMedicine</i> , 2017, 17, 88-94.	6.1	9
277	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017, 91, 982-988.	5.2	80
278	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. <i>Cardiovascular Diabetology</i> , 2017, 16, 55.	6.8	47
279	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. <i>Diabetes</i> , 2017, 66, 2278-2283.	0.6	63
280	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 597-609.	11.4	248
281	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. <i>Kidney International</i> , 2017, 91, 1300-1311.	5.2	159
282	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	1.8	34
283	Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2895.	4.0	6
284	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1197-1204.	2.4	22
285	Metformin in adults with type 1 diabetes: Design and methods of the REDUCE (Reducing Metformin Vascular Adverse Lesions (REMOVAL)): an international multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 509-516.	4.4	32
286	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1804-1813.	4.5	7
287	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	8.6	462
288	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	2.3	6

#	ARTICLE	IF	CITATIONS
289	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017, 92, 1242-1248.	5.2	24
290	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.8	77
291	[OP.4B.04] URINARY PROTEOMICS PREDICTS MORTALITY IN TYPE 2 DIABETES PATIENTS WITH MICROALBUMINURIA. <i>Journal of Hypertension</i> , 2017, 35, e38-e39.	0.5	0
292	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017, 60, 1883-1891.	6.3	18
293	Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1517-1524.	1.8	33
294	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 239-247.	4.4	77
295	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	2.3	13
296	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	6.1	101
297	Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 3699-3712.	1.9	87
298	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017, 16, 88.	6.8	41
299	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. <i>Cardiovascular Diabetology</i> , 2017, 16, 139.	6.8	27
300	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 222-230.	8.6	158
301	Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 216-227.	0.6	103
302	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. <i>Diabetes</i> , 2016, 65, 239-254.	0.6	41
303	The Danish Adult Diabetes Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 429-434.	3.0	75
304	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016, 65, 3129-3138.	0.6	22
305	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. <i>Journal of Translational Medicine</i> , 2016, 14, 203.	4.4	17
306	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016, 6, e010310.	1.9	103

#	ARTICLE	IF	CITATIONS
307	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. <i>Diabetologia</i> , 2016, 59, 1549-1557.	6.3	25
308	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016, 17, 147032031665204.	1.7	36
309	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 127.	1.8	134
310	Global Changes in Food Supply and the Obesity Epidemic. <i>Current Obesity Reports</i> , 2016, 5, 449-455.	8.4	143
311	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 137.	6.8	25
312	Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension. <i>Journal of Clinical Hypertension</i> , 2016, 18, 27-30.	2.0	5
313	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21Åyears follow-up on the Steno-2 randomised trial. <i>Diabetologia</i> , 2016, 59, 2298-2307.	6.3	378
314	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1440-1442.	2.3	8
315	Methylglyoxal is associated with changes in kidney function among individuals with screenâ€detected Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2016, 33, 1625-1631.	2.3	40
316	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. <i>International Journal of Cardiology</i> , 2016, 221, 114-121.	1.7	39
317	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1603-1608.	2.3	6
318	[OP.1D.10] THE CKD273 URINARY PROTEOMIC CLASSIFIER IS NOT A MARKER OF GENERALISED VASCULAR DISEASE IN TYPE 2 DIABETIC PATIENTS WITH NORMAL RENAL FUNCTION. <i>Journal of Hypertension</i> , 2016, 34, e14.	0.5	0
319	suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. <i>European Journal of Endocrinology</i> , 2016, 174, 745-753.	3.7	21
320	Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients â€ The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 263-269.	2.8	9
321	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 260-267.	2.0	13
322	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 321-330.	2.0	42
323	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. <i>Cardiovascular Diabetology</i> , 2016, 15, 67.	6.8	8
324	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 248-255.	2.3	49

#	ARTICLE	IF	CITATIONS
325	Cardiac ⁸² Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 371-378.	6.3	63
326	Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 789-798.	1.5	8
327	Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease â€” The Thousand & 1 Study. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 928-934.	2.3	7
328	Statins are independently associated with increased HbA1c in type 1 diabetes â€” The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016, 111, 51-57.	2.8	12
329	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. <i>Immunologic Research</i> , 2016, 64, 55-63.	2.9	37
330	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€”the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	2.2	13
331	PP.33.31. <i>Journal of Hypertension</i> , 2015, 33, e437.	0.5	0
332	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	30.5	542
333	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 59.	6.8	35
334	PP.33.30. <i>Journal of Hypertension</i> , 2015, 33, e436-e437.	0.5	0
335	Effect of 4Â½years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA_{1c} compared with multiple daily injections: a longitudinal followâ€”up study. <i>Diabetic Medicine</i> , 2015, 32, 1445-1452.	2.3	26
336	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015, 33, 2123-2132.	0.5	22
337	The renal protective effect of angiotensin receptor blockers depends on intraâ€”individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 678-686.	2.4	37
338	Cuff inflations do not affect night-time blood pressure. <i>Blood Pressure Monitoring</i> , 2015, 20, 369-372.	0.8	6
339	Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3191.	4.3	14
340	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	2.3	18
341	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4181-4188.	3.6	19
342	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	6.1	205

#	ARTICLE	IF	CITATIONS
343	Microalbuminuria: A parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 1-8.	2.8	75
344	Improved prognosis of diabetic nephropathy in type 1 diabetes. <i>Kidney International</i> , 2015, 87, 417-426.	5.2	58
345	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv1-iv5.	0.7	9
346	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv86-iv95.	0.7	33
347	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 670-674.	2.3	58
348	Global Longitudinal Strain Is Not Impaired in Type 1 Diabetes Patients Without Albuminuria. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 400-410.	5.3	86
349	Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. <i>European Journal of Endocrinology</i> , 2015, 172, 11-20.	3.7	85
350	Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2015, 28, 772-779.	2.0	13
351	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2015, 32, 1104-1109.	2.3	14
352	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015, 32, 343-352.	2.3	61
353	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. <i>Diabetic Medicine</i> , 2015, 32, 374-381.	2.3	35
354	Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study. <i>Diabetes Care</i> , 2015, 38, 1898-1903.	8.6	22
355	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3032-3040.	3.6	32
356	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	7.4	523
357	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1146-1151.	2.3	10
358	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 543-548.	6.3	43
359	Improved cardiorenal prognosis in diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2015, 11, 68-70.	9.6	15
360	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. <i>Journal of Internal Medicine</i> , 2015, 277, 362-371.	6.0	62

#	ARTICLE	IF	CITATIONS
361	Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines. <i>Journal of Research in Pharmacy Practice</i> , 2015, 4, 64.	0.7	6
362	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1195-1203.	0.7	76
363	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	3.1	33
364	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. <i>Acta Diabetologica</i> , 2014, 51, 973-980.	2.5	9
365	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. <i>Acta Diabetologica</i> , 2014, 51, 955-962.	2.5	11
366	OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, S31.	2.8	1
367	Central Hemodynamics Are Associated With Cardiovascular Disease and Albuminuria in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2014, 27, 1152-1159.	2.0	25
368	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	2.8	31
369	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2014, 57, 672-680.	6.3	71
370	Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18-year follow-up study. <i>Diabetologia</i> , 2014, 57, 2201-2207.	6.3	24
371	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2014, 31, 1138-1147.	2.3	119
372	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.7	106
373	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. <i>Diabetes Care</i> , 2014, 37, 1660-1667.	8.6	68
374	Sequential RAAS Blockade: Is It Worth the Risk?. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 159-165.	1.4	11
375	Urinary Alpha- and Pi-Glutathione S-Transferases in Adult Patients with Type 1 Diabetes. <i>Nephron Extra</i> , 2014, 4, 127-133.	1.1	4
376	Cause-Specific Mortality According to Urine Albumin Creatinine Ratio in the General Population. <i>PLoS ONE</i> , 2014, 9, e93212.	2.5	7
377	Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. <i>Diabetologia</i> , 2013, 56, 323-329.	6.3	21
378	Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. <i>Endocrine</i> , 2013, 44, 473-480.	2.3	24

#	ARTICLE	IF	CITATIONS
379	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. <i>Diabetologia</i> , 2013, 56, 1845-1855.	6.3	44
380	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. <i>Diabetologia</i> , 2013, 56, 298-310.	6.3	119
381	Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. <i>Current Diabetes Reports</i> , 2013, 13, 550-559.	4.2	127
382	Arterial Stiffness Is Associated With Cardiovascular, Renal, Retinal, and Autonomic Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 715-721.	8.6	99
383	Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 59-63.	2.3	21
384	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013, 12, 122.	6.8	30
385	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	2.2	21
386	Effects of 12-weeks™ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. <i>Diabetologia</i> , 2013, 56, 22-30.	6.3	34
387	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 604-608.	2.3	16
388	Could problems with bardoxolone methyl have been predicted?. <i>Nature Reviews Nephrology</i> , 2013, 9, 128-130.	9.6	28
389	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013, 56, 259-267.	6.3	128
390	Can ADAMTS13 Lead Us to the Paradise of Personalized Medicine?. <i>Diabetes</i> , 2013, 62, 3331-3332.	0.6	1
391	RNA oxidation and albuminuria in type 1 diabetes patients. <i>Cardiovascular Endocrinology</i> , 2013, 2, 103-105.	0.8	0
392	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 161-166.	1.7	21
393	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes. <i>Blood Pressure Monitoring</i> , 2013, 18, 156-160.	0.8	11
394	Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 563-566.	2.3	16
395	Diabetes mellitus, hypertension and albuminuria in rural <sc>Z</sc>ambia: a hospital-based survey. <i>Tropical Medicine and International Health</i> , 2013, 18, 1080-1084.	2.3	12
396	Effect of vitamin D on diabetic kidney disease in T1DM. <i>Nature Reviews Endocrinology</i> , 2013, 9, 6-7.	9.6	5

#	ARTICLE	IF	CITATIONS
397	Urinary renin and angiotensinogen in type 2 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1646-1652.	0.5	23
398	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. <i>PLoS Genetics</i> , 2012, 8, e1002921.	3.5	216
399	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 250-253.	1.7	3
400	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 118-121.	1.7	20
401	UACR—two risk markers or a 24 h collection in a minute?. <i>Nature Reviews Nephrology</i> , 2012, 8, 320-321.	9.6	1
402	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 76, n/a-n/a.	2.4	10
403	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 137-142.	1.2	18
404	Cardiovascular Autonomic Neuropathy and Subclinical Cardiovascular Disease in Normoalbuminuric Type 1 Diabetic Patients. <i>Diabetes</i> , 2012, 61, 1822-1830.	0.6	39
405	Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate. <i>Diabetes Care</i> , 2012, 35, 168-172.	8.6	46
406	Discrepancy Between Tonometric Ambulatory and Cuff—Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	2.0	3
407	Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 3304-3313.	0.6	221
408	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. <i>Lancet, The</i> , 2012, 380, 1649-1661.	13.7	378
409	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. <i>Lancet, The</i> , 2012, 380, 1662-1673.	13.7	984
410	Ambulatory Tonometric Blood Pressure Measurements in Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 453-456.	4.4	25
411	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. <i>Diabetologia</i> , 2012, 55, 2489-2493.	6.3	29
412	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 84-89.	2.8	39
413	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 71-76.	2.8	78
414	Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012, 11, 119.	6.8	14

#	ARTICLE	IF	CITATIONS
415	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. <i>Amino Acids</i> , 2012, 42, 1627-1639.	2.7	22
416	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	3.4	151
417	Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. <i>Diabetic Medicine</i> , 2012, 29, 337-344.	2.3	14
418	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012, 29, e184-90.	2.3	71
419	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 990-994.	2.3	37
420	NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012, 11, 19.	6.8	12
421	Serum Uric Acid as a New Player in the Development of Diabetic Nephropathy. , 2011, 21, 124-127.		62
422	Omics-Bioinformatics in the Context of Clinical Data. <i>Methods in Molecular Biology</i> , 2011, 719, 479-497.	0.9	14
423	NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. <i>Cardiovascular Diabetology</i> , 2011, 10, 71.	6.8	26
424	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	5.2	609
425	The Baltic Sea: Estimates of total fisheries removals 1950-2007. <i>Fisheries Research</i> , 2011, 108, 356-363.	1.7	79
426	Fibulin-1 Is a Marker for Arterial Extracellular Matrix Alterations in Type 2 Diabetes. <i>Clinical Chemistry</i> , 2011, 57, 1556-1565.	3.2	64
427	Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir. <i>Skin Research and Technology</i> , 2011, 17, 411-419.	1.6	4
428	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. <i>Journal of Negative Results in BioMedicine</i> , 2011, 10, 4.	1.4	7
429	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N ^ε (1-carboxymethyl)lysine and N ^ε (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3573-3577.	0.7	6
430	Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 2078-2083.	8.6	58
431	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. <i>Nephron Clinical Practice</i> , 2011, 118, c309-c314.	2.3	8
432	Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study. <i>Nephron Clinical Practice</i> , 2011, 118, c130-c135.	2.3	21

#	ARTICLE	IF	CITATIONS
433	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3242-3249.	0.7	24
434	Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 1192-1198.	8.6	8
435	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 442-447.	8.6	202
436	Need for better diabetes treatment for improved renal outcome. <i>Kidney International</i> , 2011, 79, S28-S32.	5.2	48
437	Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. <i>Kidney International</i> , 2011, 79, 1113-1118.	5.2	91
438	Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1081-1085.	8.6	98
439	Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. <i>Cardiovascular Diabetology</i> , 2011, 10, 70.	6.8	14
440	Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1025-1031.	4.5	53
441	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.7	22
442	Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. <i>Journal of Hypertension</i> , 2010, 28, 2316-2322.	0.5	119
443	Telomere length predicts all-cause mortality in patients with type 1 diabetes. <i>Diabetologia</i> , 2010, 53, 45-48.	6.3	76
444	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010, 53, 1576-1580.	6.3	30
445	Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 2129-2133.	6.3	34
446	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. <i>Diabetologia</i> , 2010, 53, 2562-2568.	6.3	19
447	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. <i>Clinical Proteomics</i> , 2010, 6, 105-114.	2.1	28
448	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. <i>Proteome Science</i> , 2010, 8, 4.	1.7	36
449	Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. <i>BMC Nephrology</i> , 2010, 11, 29.	1.8	71
450	Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 697-705.	1.6	20

#	ARTICLE	IF	CITATIONS
451	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. <i>Diabetic Medicine</i> , 2010, 27, 1144-1150.	2.3	111
452	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. <i>PLoS ONE</i> , 2010, 5, e13421.	2.5	117
453	Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy. <i>Diabetes Care</i> , 2010, 33, 2304-2309.	8.6	58
454	Osteoprotegerin and Mortality in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2010, 33, 2561-2566.	8.6	53
455	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. <i>Diabetes Care</i> , 2010, 33, 1567-1572.	8.6	98
456	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. <i>Diabetes</i> , 2010, 59, 2027-2032.	0.6	109
457	Vitamin D Levels and Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2238-2243.	8.6	126
458	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. <i>Platelets</i> , 2010, 21, 525-532.	2.3	30
459	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 449-457.	0.7	111
460	Proteomic biomarkers in diabetic nephropathy--reality or future promise?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2843-2845.	0.7	29
461	Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2010, 33, 1320-1324.	8.6	106
462	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	12.4	273
463	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. <i>PLoS ONE</i> , 2010, 5, e13051.	2.5	51
464	Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria. <i>Diabetes Care</i> , 2009, 32, 1873-1879.	8.6	147
465	Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition. <i>Diabetes Care</i> , 2009, 32, 1684-1688.	8.6	64
466	Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 360, 416-418.	27.0	12
467	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3343-3349.	0.7	11
468	YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. <i>Diabetes Care</i> , 2009, 32, 323-328.	8.6	117

#	ARTICLE	IF	CITATIONS
469	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009, 52, 46-49.	6.3	32
470	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 966-977.	4.4	42
471	Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes. <i>Diabetes</i> , 2009, 58, 1668-1671.	0.6	194
472	Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. <i>Platelets</i> , 2009, 20, 513-519.	2.3	28
473	Long-term prevention of diabetic nephropathy: an audit. <i>Diabetologia</i> , 2008, 51, 956-961.	6.3	24
474	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2008, 51, 2100-2107.	6.3	70
475	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008, 2, 997-1007.	1.6	64
476	Is renal Na ⁺ /K ⁺ -ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?. <i>Journal of Physiology</i> , 2008, 586, 5283-5283.	2.9	1
477	Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3186-3191.	3.6	71
478	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008, 73, 1419-1425.	5.2	121
479	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 747-752.	8.6	121
480	Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years. <i>Diabetes Care</i> , 2008, 31, 1170-1176.	8.6	106
481	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 1177-1182.	8.6	99
482	Urinary Proteomics in Diabetes and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1283-1290.	6.1	267
483	ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 771-779.	6.1	80
484	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2008, 74, 649-654.	5.2	124
485	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 731-738.	1.2	74
486	Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. <i>PLoS ONE</i> , 2008, 3, e3363.	2.5	83

#	ARTICLE	IF	CITATIONS
487	Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. <i>Journal of Hypertension</i> , 2007, 25, 2479-2485.	0.5	93
488	Pregnancy-associated plasma protein-A in a large cohort of Type-1 diabetic patients with and without diabetic nephropathy—a prospective follow-up study. <i>Diabetic Medicine</i> , 2007, 24, 1381-1385.	2.3	12
489	Renoprotective effects of renin-angiotensin-system inhibitors. <i>Lancet</i> , The, 2006, 367, 898-899.	13.7	4
490	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. <i>Kidney International</i> , 2006, 70, 536-542.	5.2	189
491	Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. <i>Diabetologia</i> , 2006, 49, 11-19.	6.3	82
492	Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history. <i>Current Diabetes Reports</i> , 2006, 6, 479-483.	4.2	148
493	Renoprotection by blocking the RAAS in diabetic nephropathy—fact or fiction?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2354-2357.	0.7	25
494	Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2030-2031.	0.7	4
495	Aldosterone synthase (CYP11B2) 344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006, 66, 173-180.	1.2	6
496	Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. <i>Diabetes</i> , 2006, 55, 3550-3555.	0.6	77
497	Comparison of the Effects of Vitamins and/or Mineral Supplementation on Glomerular and Tubular Dysfunction in Type 2 Diabetes: Response to Farvid et al.. <i>Diabetes Care</i> , 2006, 29, 747-748.	8.6	4
498	Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 2006, 29, 334-339.	8.6	156
499	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. <i>Kidney International</i> , 2005, 67, 2325-2329.	5.2	41
500	Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. <i>Kidney International</i> , 2005, 68, 1250-1257.	5.2	70
501	Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study. <i>Kidney International</i> , 2005, 68, 1446-1450.	5.2	64
502	Beneficial impact of spironolactone in diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 2829-2836.	5.2	201
503	Renoprotection with and without blood pressure reduction. <i>Kidney International</i> , 2005, 67, S54-S59.	5.2	16
504	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. <i>Diabetologia</i> , 2005, 48, 1439-1444.	6.3	84

#	ARTICLE	IF	CITATIONS
505	Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 1988-1994.	8.6	80
506	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. <i>Kidney International</i> , 2004, 66, 1180-1186.	5.2	40
507	Progression of nephropathy in type 2 diabetic patients. <i>Kidney International</i> , 2004, 66, 1596-1605.	5.2	270
508	Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. <i>Diabetologia</i> , 2004, 47, 1936-1939.	6.3	214
509	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. <i>BMJ: British Medical Journal</i> , 2004, 328, 1105.	2.3	337
510	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. <i>Seminars in Nephrology</i> , 2004, 24, 147-157.	1.6	57
511	Birth weight - a risk factor for progression in diabetic nephropathy?. <i>Journal of Internal Medicine</i> , 2003, 253, 343-350.	6.0	16
512	Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy. <i>Diabetes Care</i> , 2003, 26, 1501-1506.	8.6	60
513	Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2003, 26, 911-916.	8.6	52
514	Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2003, 26, 1258-1264.	8.6	325
515	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 293-297.	0.7	21
516	Optimal dose of losartan for renoprotection in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1413-1418.	0.7	64
517	Risk Factors for Development of Incipient and Overt Diabetic Nephropathy in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2002, 25, 859-864.	8.6	209
518	Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy. , 2002, , 97-101.		0
519	Pregnancy and progression of diabetic nephropathy. <i>Diabetologia</i> , 2002, 45, 36-41.	6.3	115
520	Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?. <i>Kidney International</i> , 2002, 62, 192-198.	5.2	30
521	Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1. <i>American Journal of Kidney Diseases</i> , 2001, 38, 1376-1380.	1.9	27
522	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively ¹¹ See Editorial by Steffes, p. 378. <i>Kidney International</i> , 2001, 60, 277-283.	5.2	89

#	ARTICLE	IF	CITATIONS
523	Progression of diabetic nephropathy. <i>Kidney International</i> , 2001, 59, 702-709.	5.2	283
524	Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2001, 18, 199-205.	2.3	152
525	Preventing diabetic nephropathy: an audit. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 471-477.	1.2	5
526	Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 349-356.	1.2	18
527	Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2001, 24, 177-178.	8.6	9
528	Remission of Nephrotic-Range Albuminuria in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2001, 24, 1972-1977.	8.6	63
529	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. <i>Kidney International</i> , 2000, 57, 601-606.	5.2	250
530	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000, 57, S32-S37.	5.2	37
531	Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000, 23, 1725-1730.	8.6	79
532	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000, 23, 30-33.	8.6	53
533	QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2000, 60, 323-332.	1.2	87
534	Serum Creatinine and Other Measures of GFR in Diabetes. , 2000, , 95-101.		0
535	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International, Supplement</i> , 2000, 75, S32-7.	0.1	9
536	Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. <i>Diabetes Care</i> , 1999, 22, 478-483.	8.6	88
537	Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999, 16, 388-394.	2.3	16
538	Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999, 16, 555-562.	2.3	68
539	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. <i>Kidney International</i> , 1999, 56, S101-S105.	5.2	80
540	Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus a sign of vascular damage in patients with diabetic nephropathy?. <i>Fibrinolysis and Proteolysis</i> , 1999, 13, 142-147.	1.1	1

#	ARTICLE	IF	CITATIONS
541	Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. Diabetes Care, 1999, 22, 491-494.	8.6	13
542	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney International, 1998, 53, 1002-1006.	5.2	91
543	Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus. , 1998, 15, 900-919.		53
544	Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. Diabetes Care, 1998, 21, 2007-2015.	8.6	25
545	Diabetes and Risk of Adverse Events With Calcium Antagonists. Diabetes Care, 1998, 21, 1779-1780.	8.6	9
546	Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 405-414.	1.2	9
547	Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. Clinical Science, 1998, 95, 709-717.	4.3	7
548	Doubling of serum creatinine: is it sensitive and relevant?. Nephrology Dialysis Transplantation, 1998, 13, 244-246.	0.7	15
549	Serum Creatinine and other Measures of GFR in Diabetes. , 1998, , 97-102.		0
550	Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. Diabetes, 1997, 46, 1182-1188.	0.6	153
551	Polymorphisms in the Interleukin-1 Gene Cluster Do Not Contribute to the Genetic Susceptibility of Diabetic Nephropathy in Caucasian Patients With IDDM. Diabetes, 1997, 46, 1075-1076.	0.6	25
552	Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment. Diabetes, 1997, 46, 481-487.	0.6	60
553	Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation, 1997, 57, 427-434.	1.2	32
554	Renal Protection in Diabetes-An Emerging Role for Calcium Antagonists. Cardiology, 1997, 88, 56-62.	1.4	12
555	Left Ventricular Hypertrophy in Non-insulin-dependent Diabetic Patients With and Without Diabetic Nephropathy. , 1997, 14, 538-546.		41
556	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes, 1997, 46, 481-487.	0.6	24
557	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes, 1997, 46, 1182-1188.	0.6	64
558	Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy. Fibrinolysis, 1996, 10, 331-335.	0.5	7

#	ARTICLE	IF	CITATIONS
559	Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. <i>Thrombosis Research</i> , 1996, 81, 485-490.	1.7	53
560	Renal protection in diabetes: an emerging role for calcium antagonists. <i>Journal of Hypertension</i> , 1996, 14, S21-S22.	0.5	23
561	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1019-1023.	0.7	18
562	Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1996, 39, 1590-1597.	6.3	69
563	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. <i>Kidney International</i> , 1996, 49, 1778-1782.	5.2	63
564	Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. <i>Kidney International</i> , 1996, 50, 579-585.	5.2	50
565	Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs. <i>Nephrology</i> , 1996, 2, s45-s48.	1.6	0
566	Fish Oil in Diabetic Nephropathy. <i>Diabetes Care</i> , 1996, 19, 1214-1219.	8.6	50
567	Increased Plasma Apolipoprotein(a) Levels in IDDM Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 1996, 19, 1382-1387.	8.6	17
568	Increased Tissue Factor Pathway Inhibitor Activity in IDDM Patients With Nephropathy. <i>Diabetes Care</i> , 1996, 19, 441-445.	8.6	29
569	Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy. <i>Diabetes</i> , 1996, 45, 367-369.	0.6	63
570	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1019-1023.	0.7	36
571	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. <i>BMJ: British Medical Journal</i> , 1996, 313, 591-594.	2.3	158
572	Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. <i>BMJ: British Medical Journal</i> , 1996, 313, 779-784.	2.3	382
573	Genetics of diabetic nephropathy.. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 2509-2517.	6.1	85
574	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1996, 45, 367-369.	0.6	21
575	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. <i>Diabetologia</i> , 1995, 38, 798-803.	6.3	87
576	Procoagulant activity and intimal dysfunction in IDDM. <i>Diabetologia</i> , 1995, 38, 73-78.	6.3	28

#	ARTICLE	IF	CITATIONS
577	Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. <i>Kidney International</i> , 1995, 47, 1726-1731.	5.2	74
578	Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy?. <i>Diabetes</i> , 1995, 44, 1405-1407.	0.6	77
579	Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin I-Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients. <i>Diabetes</i> , 1995, 44, 489-494.	0.6	184
580	Unchanged Incidence of Diabetic Nephropathy in IDDM Patients. <i>Diabetes</i> , 1995, 44, 739-743.	0.6	109
581	On the Mechanisms of Blunted Nocturnal Decline in Arterial Blood Pressure in NIDDM Patients With Diabetic Nephropathy. <i>Diabetes</i> , 1995, 44, 783-789.	0.6	87
582	Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience. <i>American Journal of Kidney Diseases</i> , 1995, 26, 99-107.	1.9	99
583	Short stature and diabetic nephropathy. <i>BMJ: British Medical Journal</i> , 1995, 310, 296-297.	2.3	55
584	Low birth weight. A risk factor for development of diabetic nephropathy?. <i>Diabetes</i> , 1995, 44, 1405-1407.	0.6	26
585	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. <i>Diabetes</i> , 1995, 44, 489-494.	0.6	70
586	Unchanged incidence of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1995, 44, 739-743.	0.6	39
587	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1995, 44, 783-789.	0.6	30
588	Impact of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. <i>Diabetes</i> , 1994, 43, 1108-1113.	0.6	57
589	Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V. <i>Diabetes Care</i> , 1994, 17, 1247-1251.	8.6	162
590	Glomerular size-and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 195-201.	6.3	37
591	Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. <i>Diabetologia</i> , 1994, 37, 511-516.	6.3	179
592	Monitoring kidney function in diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 708-712.	6.3	28
593	The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus. <i>Fibrinolysis</i> , 1994, 8, 22-24.	0.5	35
594	The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 1994, 3, 292-300.	2.0	51

#	ARTICLE	IF	CITATIONS
595	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1994, 43, 1108-1113.	0.6	29
596	Reduction in albuminuria predicts diminished progression in diabetic nephropathy. <i>Kidney International</i> , Supplement, 1994, 45, S145-9.	0.1	16
597	Monitoring kidney function in diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 708-712.	6.3	5
598	Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1993, 36, 438-444.	6.3	49
599	Calcium Antagonists and the Diabetic Hypertensive Patient. <i>American Journal of Kidney Diseases</i> , 1993, 21, S47-S52.	1.9	8
600	Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy. <i>American Journal of Kidney Diseases</i> , 1993, 22, 188-195.	1.9	106
601	Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients. <i>Diabetes</i> , 1993, 42, 715-719.	0.6	129
602	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1993, 42, 715-719.	0.6	51
603	Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1992, 52, 513-521.	1.2	30
604	Placebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non-Insulin-Dependent Diabetic Patients With Primary Hypertension. <i>American Journal of Hypertension</i> , 1992, 5, 257-265.	2.0	16
605	Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. <i>Diabetologia</i> , 1992, 35, 447-451.	6.3	91
606	Red cell Na ⁺ /Li ⁺ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. <i>Kidney International</i> , 1991, 39, 135-140.	5.2	34
607	Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1991, 34, 655-661.	6.3	332